StreetInsider.com News Articles

Form RW Alzamend Neuro, Inc.

Fri, 09 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261009/27168790.html

Form 8-K Alzamend Neuro, Inc. For: Sep 29

Tue, 29 Sep 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260929/27116993.html

Alzamend Neuro regains Nasdaq compliance with $5.8M equity

Wed, 16 Sep 2026 08:00:30 -0400

Alzamend Neuro, Inc. (Nasdaq: ALZN) announced it has received notification from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million.

According to the company's quarterly report on Form 10-Q for the quarter ended July 31, 2026, filed with the U.S. Securities and Exchange Commission on September 10, 2026, Alzamend reported stockholders' equity of $5,802,680. Nasdaq confirmed the matter is closed.

The compliance issue originated on March 20, 2026, when Nasdaq notified Alzamend that it did not meet the minimum market value of listed securities requirement. The company was given 45 days

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Wed, 16 Sep 2026 08:00:00 -0400

ATLANTA, Sept. 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated September 14, 2026, informing Alzamend that it

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Wed, 16 Sep 2026 08:00:00 -0400

Form 10-Q Alzamend Neuro, Inc. For: Jul 31

Thu, 10 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260910/27048877.html

Form PRE 14A Alzamend Neuro, Inc. For: Oct 19

Fri, 28 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260828/26998495.html

Form PRE 14A Alzamend Neuro, Inc. For: Oct 19

Fri, 28 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260828/26998495.html

Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders

Fri, 21 Aug 2026 16:35:44 -0400

Alzamend Neuro (NASDAQ: ALZN) filed for up to 98,388,305 share offering by selling stockholders.

Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders

Fri, 21 Aug 2026 16:35:44 -0400

Alzamend Neuro (NASDAQ: ALZN) filed for up to 98,388,305 share offering by selling stockholders.

Form S-1 Alzamend Neuro, Inc.

Fri, 21 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260821/26961797.html

Form S-1 Alzamend Neuro, Inc.

Fri, 21 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260821/26961797.html

Form 4/A Alzamend Neuro, Inc. For: Jul 31 Filed by: Hyperscale Data, Inc.

Thu, 20 Aug 2026 21:18:00 -0400

si-local-file:///var/storage/secattach/20260820/26957597.html

Form 4/A Alzamend Neuro, Inc. For: Jul 31 Filed by: Hyperscale Data, Inc.

Thu, 20 Aug 2026 21:18:00 -0400

si-local-file:///var/storage/secattach/20260820/26957597.html

Form 3/A Alzamend Neuro, Inc. For: Jul 29 Filed by: Hyperscale Data, Inc.

Thu, 20 Aug 2026 21:17:00 -0400

si-local-file:///var/storage/secattach/20260820/26957596.html

Form 3/A Alzamend Neuro, Inc. For: Jul 29 Filed by: Hyperscale Data, Inc.

Thu, 20 Aug 2026 21:17:00 -0400

si-local-file:///var/storage/secattach/20260820/26957596.html

Alzamend Neuro fMRI data accepted for neuroscience conference poster

Thu, 20 Aug 2026 08:00:39 -0400

Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.

The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.